|
ACP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.25139999987923E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.99209999999628E-05 |
| Normal-vs-Stage2 |
6.944500E-03 |
| Normal-vs-Stage3 |
6.52979999959946E-07 |
| Normal-vs-Stage4 |
4.14280000304856E-08 |
| Stage1-vs-Stage2 |
8.784400E-01 |
| Stage1-vs-Stage3 |
8.630000E-02 |
| Stage1-vs-Stage4 |
5.543800E-03 |
| Stage2-vs-Stage3 |
3.146200E-01 |
| Stage2-vs-Stage4 |
7.811800E-02 |
| Stage3-vs-Stage4 |
2.928800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.12060000004399E-07 |
| Normal-vs-AfricanAmerican |
1.059220E-01 |
| Normal-vs-Asian |
1.575220E-04 |
| Caucasian-vs-AfricanAmerican |
3.583600E-01 |
| Caucasian-vs-Asian |
6.549600E-01 |
| AfricanAmerican-vs-Asian |
5.742800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.29499999999661E-05 |
| Normal-vs-Female |
1.27610000000278E-06 |
| Male-vs-Female |
8.791800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.53309999999718E-05 |
| Normal-vs-Age(41-60Yrs) |
1.9997799999949E-05 |
| Normal-vs-Age(61-80Yrs) |
1.70579999999587E-05 |
| Normal-vs-Age(81-100Yrs) |
5.809600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.063000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.298200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.508400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.087000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.246600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.600400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.480840E-01 |
| Classical-VS-Follicular |
6.797600E-02 |
| Classical-VS-Other |
6.744200E-01 |
| Classical-VS-Normal |
2.1400999999921E-05 |
| Tall-VS-Follicular |
6.957700E-03 |
| Tall-VS-Other |
3.900200E-01 |
| Tall-VS-Normal |
2.04619999999434E-06 |
| Follicular-VS-Other |
9.065000E-01 |
| Follicular-VS-Normal |
8.637800E-02 |
| Other-VS-Normal |
4.955400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.42949999999365E-05 |
| Normal-vs-N1 |
8.08669999852185E-08 |
| N0-vs-N1 |
1.571580E-02 |
|
|
